
Feb 21 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS
J&J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12
J&J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA
Source text: ID:nPn7jMWf9a
Further company coverage: JNJ.N